Net Profit Margins
CUE BIOPHARMA INC’s revenue jumped +Inf% since last year same period to $0.45Mn in the Q3 2018. On a quarterly growth basis, CUE BIOPHARMA INC has generated 161.05% jump in its revenue since last 3-months.
CUE BIOPHARMA INC’s net profit fell -149.58% since last year same period to $-12.56Mn in the Q3 2018. On a quarterly growth basis, CUE BIOPHARMA INC has generated -72.04% fall in its net profits since last 3-months.
CUE BIOPHARMA INC’s net profit margin jumped NaN% since last year same period to -2797.1% in the Q3 2018. On a quarterly growth basis, CUE BIOPHARMA INC has generated 34.1% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter
EPS Estimate Current Year
CUE BIOPHARMA INC’s earning per share (EPS) estimates for the current quarter stand at -0.34 - a 10.53% jump from last quarter’s estimates.
CUE BIOPHARMA INC’s earning per share (EPS) estimates for the current year stand at -0.34.
Return on Assets (ROA)
Return on Equity (ROE)
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. CUE BIOPHARMA INC’s return on assets (ROA) stands at -0.37.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. CUE BIOPHARMA INC’s return on equity (ROE) stands at -0.82.
|Earnings Date||Estimated EPS||Reported EPS||Surprise %|
CUE BIOPHARMA INC
21 Erie Street, Cambridge, MA, United States, 02139